WallStreetZenWallStreetZen

NASDAQ: TMDX
Transmedics Group Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Transmedics Group earnings were $71.7M for the trailing 12 months ending Jun 30, 2025, with 2,562.5% growth year over year. The latest TMDX earnings report on Jun 30, 2025 announced Q2 2025 earnings of $34.9M, up 35.9% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, TMDX reported annual earnings of $35.5M, with -241.7% growth. The next TMDX earnings date is Nov 11, 2025.

TMDX past earnings growth

How has TMDX's earnings growth performed historically?

Company
2,562.5%
Industry
84.35%
Market
34.06%
TMDX's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
TMDX's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Market Performance
TMDX's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

TMDX earnings history

Current Revenue
$531.3M
Current Earnings
$71.7M
Current Profit Margin
13.5%

TMDX Return on Equity

Current Company
28%
Current Industry
15.2%
Current Market
30.7%
TMDX's Return on Equity (28%)... subscribe to Premium to read more.
High Return on Equity Performance

TMDX undefined

Current Company
8.6%
Current Industry
8.9%
TMDX is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when TMDX announces earnings.

TMDX undefined

Current Company
10.58%
Current Industry
10.6%
TMDX has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

TMDX vs Medical Device Stocks

TickerEBITDAEarningsY/Y EarningsEPS
TMDX$113.85M$71.66M+2,562.50%$2.13
ITGR$295.76M$82.66M+1.65%$2.42
GKOS-$47.80M-$92.79MN/A-$1.64
BRKR$351.10M$79.60M-13.44%$0.52
LIVN-$66.76M-$211.32MN/A-$3.87
View Top Medical Device Stocks

TMDX earnings dates

Next earnings date
Nov 11, 2025

Transmedics Group Earnings Reports & History FAQ

What were Transmedics Group's earnings last quarter?

On TMDX's earnings call on Invalid Date, Transmedics Group (NASDAQ: TMDX) reported Q2 2025 earnings per share (EPS) of $1.03, up 178.38% year over year. Total TMDX earnings for the quarter were $34.91 million. In the same quarter last year, Transmedics Group's earnings per share (EPS) was $0.37.

If you're new to stock investing, here's how to buy Transmedics Group stock.

When does Transmedics Group report earnings?

The next TMDX earnings call is Invalid Date. Add TMDX to your watchlist to be reminded of Transmedics Group's next earnings date.

Is Transmedics Group profitable or losing money?

As of the last Transmedics Group earnings report, Transmedics Group is currently profitable. Transmedics Group's net profit (also called net income) for the twelve months ending Jun 30, 2025 was $71.66 million, a 2,288.73% increase year over year.

What was TMDX's earnings growth in the past year?

As of Transmedics Group's earnings date in Invalid Date, Transmedics Group's earnings has grown 2,562.5% year over year. This is 2,478.15 percentage points higher than the US Medical Devices industry earnings growth rate of 84.35%. TMDX earnings in the past year totalled $71.66 million.

What are Transmedics Group's earnings expectations?

The current EPS estimate for Transmedics Group's earnings report in Invalid Date is $0.36.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.